Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), is a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that the enrollment in the fourth and final cohort in the Phase 1 portion of the ongoing Phase 1/2 trial of Actimab-A has been completed and that enrollment of the maximum tolerated dose (MTD) confirmatory patients is expected to begin in November. The Phase 2 portion of the trial may begin subsequent to the completion of the confirmatory portion of the Phase 1 trial. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy. The Phase 1 trial results, including those from the final patient cohort, will be made available at the 57th American Society of Hematology Annual Meeting being held December 5 – 8, 2015 in Orlando, Florida.

Patients in this fourth and final cohort are being treated at 2.0 μCi/kg dose level of Actimab-A. To date, three cohorts of patients have been treated at dose levels of 0.5, 1.0 and 1.5 μCi/kg per fractionated dose, respectively. The treatment consists of two fractionated doses one week apart following cytoreduction with low dose cytarabine. Maximum tolerated dose (MTD) has not been reached yet and there was no peri-induction mortality among these high risk patients. However, dose dependent responses have been observed. In this Phase 1/2 trial design, maximum tolerated dose will automatically become the Phase 2 portion dose.

In the previously completed third cohort in which patients received two doses of Actimab-A at 1.5 μCi/kg per dose, two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). “We are pleased to have reached this important milestone for the Phase 1 portion of the trial,” said Dr. Kaushik Dave, the CEO of Actinium Pharmaceuticals. “With patient enrollment complete, we look forward to continuing our progression to the Phase 2 portion of the Actimab-A trial.” (Original Source)

Shares of Actinium Pharmaceuticals closed yesterday at $2.20. ATNM has a 1-year high of $8.12 and a 1-year low of $1.52. The stock’s 50-day moving average is $2.17 and its 200-day moving average is $2.50.

Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.